Brief: ExpreS2ion Biotech Says First Subject Vaccinated In COVID-19 Phase 3 Clinical Trial For ABNcoV2 As A Booster Vaccine
02/09/2022 21:11
Sept 2 (Reuters) - ExpreS2ion Biotech Holding AB
EXPRS2.ST :
* FIRST SUBJECT VACCINATED IN COVID-19 PHASE III CLINICAL
TRIAL
FOR ABNCOV2 AS A BOOSTER VACCINE
Source text for Eikon: ID:nWkr6vCBL4
Further company coverage: EXPRS2.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations